Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data-Reference-Cited by-同舟云学术

Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data

Published:2020-05 Issue:5 Volume:82 Page:1150-1157
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Frew John W.,Jiang Caroline S.,Singh Neha,Grand David,Navrazhina Kristina,Vaughan Roger,Krueger James G.

Funder

National Center for Advancing Translational Sciences, National Institutes of Health

NIH

National Institute of General Medical Sciences

AbbVie

Amgen

BMS

Boehringer

EMD Serono

Innovaderm

Kineta

LEO Pharma

Novan

Novartis

Paraxel

Pfizer

Regeneron

Vitae

Publisher

Elsevier BV

Subject

Dermatology

Reference18 articles.

1. Okun MM Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment;Kimball;Br J Dermatol,2014

2. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo controlled portion of a phase 2 adalimumab study;Kimball;J Eur Acad Dermatol Venereol,2016

3. Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review;Ali;J Am Acad Dermatol,2020

4. Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs bias in outcome measures in moderate and severe disease;Frew;J Eur Acad Dermatol Venereol,2019

5. Development and validation of the International Hidradenitis Suppurativa Severity Scoring System (IHS4), a novel dynamic scoring system to assess HS severity;Zouboulis;Br J Dermatol,2017

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials;Journal of the European Academy of Dermatology and Venereology;2024-08-05

2. Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity;Australasian Journal of Dermatology;2024-06-25

3. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial;British Journal of Dermatology;2024-04-05

4. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials;British Journal of Dermatology;2024-03-12

5. Significant spontaneous daily fluctuation of inflammatory nodules and abscesses but not of draining tunnels in hidradenitis suppurativa/acne inversa;Journal of the European Academy of Dermatology and Venereology;2024-02-13